课题基金 / 基金详情

Netrins and Gene Therapy After Spinal Cord Injury

Netrins and Gene Therapy After Spinal Cord Injury
Netrins 和脊髓损伤后的基因治疗
批准号:
6364875
负责人:
MARK H. TUSZYNSKI
金额:
$19.29万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-15 至 2004-06-30

项目摘要

项目成果

MARK H. TUSZYNSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Progress in preclinical research over the last two decades has contributed substantially to our knowledge of factors that can promote axonal growth after spinal cord injury. However, there is a relative paucity of information regarding molecular mechanisms that might augment and guide axonal growth after injury in the adult. One important family of molecules that plays an important role in axon growth and guidance during development is the netrin family of diffusible molecules, and their associated receptors, DCC (deleted colon carcinoma) and UNC-5 family proteins. This project will characterize the natural expression of netrin and its receptors after adult spinal cord injury, then manipulate the potential ability of axons to respond to these molecules using ex vivo gene delivery of netrin to the injured spinal cord. Two specific aims will be examined: Specific Aim 1: Characterize expression of netrins and their receptors (members of the DCC and UNC-5 family) in the intact and lesioned adult rat spinal cord. Specific Aim 2: Determine whether netrin over-expression in the injured adult spinal cord influences the extent or direction of axonal growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing human neural progenitor cells (hNPCs) to FDA IND approval
  • 批准号:
    10642228
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2023
  • 负责人:
    MARK H. TUSZYNSKI
  • 依托单位:
The Primate Corticospinal Connectome and Transcriptome - Supplement
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
海外基金